文献速递泌尿生殖MR

前瞻性PI-RADS v2.1非典型良性前列腺增生结节伴显著弥散受限:多参数MRI检测临床显著前列腺癌

Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
PubMed 文献 · AJR Am J Roentgenol · 2020-09-02

本研究回顾性纳入1238例接受3T多参数MRI并按PI-RADS v2.1前瞻性报告的患者,比较2+1移行区病灶(非典型良性前列腺增生结节伴弥散受限,DWI评分4-5)与常规3+0移行区病灶的临床显著前列腺癌检出率。结果显示2+1病灶的临床显著前列腺癌检出率为6%(3/49),3+0病灶为11%(7/61),两组间无显著差异(p=0.31)。

要点

  • PI-RADS v2.1定义的2+1移行区病灶(非典型良性前列腺增生结节伴显著弥散受限)临床显著前列腺癌检出率低(6%)。
  • 2+1病灶与常规3+0移行区病灶的临床显著前列腺癌检出率无显著差异(6% vs 11%,p=0.31)。
  • 2+1病灶中未发现与临床显著前列腺癌相关的临床或影像变量。

核心结论

  • 非典型良性前列腺增生结节伴显著弥散受限的临床显著前列腺癌检出率低(6%),与常规3+0移行区病灶(11%)无显著差异(p=0.31)。

研究设计与样本

  • 回顾性研究,纳入无已知前列腺癌或未治疗GG1前列腺癌的男性,接受3T多参数MRI并按PI-RADS v2.1前瞻性报告。
  • 最终样本为至少有一个PI-RADS 3类移行区病灶并接受靶向穿刺活检的患者。
  • 在1238例符合条件的患者中,2+1病灶报告于6%(n=69)的患者,3+0移行区病灶报告于7%(n=87)的患者。
  • 采用广义估计方程比较两组临床显著前列腺癌检出率,采用Kruskal-Wallis检验和Fisher精确检验分析2+1病灶中临床显著前列腺癌与临床及影像变量的关联。

诊断标准与关键数值

  • PI-RADS v2.1定义移行区非典型良性前列腺增生结节为包膜不完整或缺失的移行区病灶(T2评分2分),若伴显著弥散受限(DWI评分4-5分),则整体PI-RADS类别从2类升级为3类(2+1移行区病灶)。
  • 49例接受靶向活检的2+1病灶患者中,无前列腺癌、GG1前列腺癌和临床显著前列腺癌分别占84%(n=41)、10%(n=5)和6%(n=3)。
  • 61例接受靶向活检的3+0病灶患者中,无前列腺癌、GG1前列腺癌和临床显著前列腺癌分别占74%(n=45)、15%(n=9)和11%(n=7)。
  • 2+1病灶与3+0病灶的临床显著前列腺癌检出率无显著差异(p=0.31)。
  • 所有临床显著前列腺癌均为GG2, except one 3+0 lesion with a GG3 tumor.

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. On the basis of expert consensus, PI-RADS version 2.1 (v2.1) introduced the transition zone (TZ) atypical benign prostatic hyperplasia (BPH) nodule, defined as a TZ lesion with an incomplete or absent capsule (T2 score, 2). PI-RADS v2.1 also included a revised scoring pathway whereby such nodules, if exhibiting marked restricted diffusion (DWI score, 4-5), are upgraded from overall PI-RADS category 2 to category 3 (2 + 1 TZ lesions). OBJECTIVE. The purpose of this study was to compare the rates of detection of clinically significant prostate cancer (csPCa) in prospectively reported 2 + 1 TZ lesions, as defined by PI-RADS v2.1, and conventional 3 + 0 TZ lesions with targeted biopsy as the reference standard. METHODS. This retrospective study included men with no known PCa or with treatment-naïve grade group (GG) 1 PCa who underwent 3-T multiparametric MRI of the prostate with prospective reporting by means of PI-RADS v2.1. Patients with at least one PI-RADS category 3 TZ lesion who underwent targeted biopsy formed the final sample. Biopsy results were summarized descriptively for 2 + 1 and 3 + 0 lesions. Generalized estimating equations were used to compare csPCa detection rates between groups. Associations between csPCa in 2 + 1 lesions and patient age, PSA level, prostate volume, PSA density, biopsy history, lesion size, and lesion ADC were tested with Kruskal-Wallis and Fisher exact tests. RESULTS. Among 1238 eligible patients who underwent MRI reported with PI-RADS v2.1, 2 + 1 lesions were reported in 6% (n = 69) and 3 + 0 TZ lesions in 7% (n = 87) of patients. No PCa, GG1 PCa, or csPCa was found in 84% (n = 41), 10% (n = 5), and 6% (n = 3) of 49 patients with 2 + 1 lesions who underwent targeted biopsy. Nor were they found in 74% (n = 45), 15% (n = 9), and 11% (n = 7) of 61 patients with 3 + 0 lesions who underwent targeted biopsy. The csPCa detection rate was not significantly different between 2 + 1 and 3 + 0 lesions (p = .31). All cases of csPCa were GG2, except for one 3 + 0 lesion with a GG3 tumor. No clinical or imaging variable was associated with csPCa in 2 + 1 lesions. CONCLUSION. The rate of csPCa in atypical BPH nodules with marked restricted diffusion was low (6%) and not significantly different from that of conventional 3 + 0 TZ lesions (11%). CLINICAL IMPACT. The results provide prospective clinical data about the revised TZ scoring criterion and pathway in PI-RADS v2.1 for atypical BPH nodules with marked restricted diffusion.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Costa DN, Jia L, Subramanian N, et al. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI. AJR Am J Roentgenol. 2020. PMID: 32876473. doi:10.2214/AJR.20.24370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。